Challenges and Alternatives to Evaluation Methods and Regulation Approaches for Medical Apps as Mobile Medical Devices: International and Multidisciplinary Focus Group Discussion.

alternative approaches evaluation methods focus group study logic model medical apps mobile medical device regulation mobile medical devices mobile phone

Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
30 Sep 2024
Historique:
received: 28 11 2023
accepted: 24 07 2024
revised: 15 05 2024
medline: 1 10 2024
pubmed: 30 9 2024
entrez: 30 9 2024
Statut: epublish

Résumé

The rapid proliferation of medical apps has transformed the health care landscape by giving patients and health care providers unprecedented access to personalized health information and services. However, concerns regarding the effectiveness and safety of medical apps have raised questions regarding the efficacy of randomized controlled trials (RCTs) in the evaluation of such apps and as a requirement for their regulation as mobile medical devices. This study aims to address this issue by investigating alternative methods, apart from RCTs, for evaluating and regulating medical apps. Using a qualitative approach, a focus group study with 46 international and multidisciplinary public health experts was conducted at the 17th World Congress on Public Health in May 2023 in Rome, Italy. The group was split into 3 subgroups to gather in-depth insights into alternative approaches for evaluating and regulating medical apps. We conducted a policy analysis on the current regulation of medical apps as mobile medical devices for the 4 most represented countries in the workshop: Italy, Germany, Canada, and Australia. We developed a logic model that combines the evaluation and regulation domains on the basis of these findings. The focus group discussions explored the strengths and limitations of the current evaluation and regulation methods and identified potential alternatives that could enhance the quality and safety of medical apps. Although RCTs were only explicitly mentioned in the German regulatory system as one of many options, an analysis of chosen evaluation methods for German apps on prescription pointed toward a "scientific reflex" where RCTs are always the chosen evaluation method. However, this method has substantial limitations when used to evaluate digital interventions such as medical apps. Comparable results were observed during the focus group discussions, where participants expressed similar experiences with their own evaluation approaches. In addition, the participants highlighted numerous alternatives to RCTs. These alternatives can be used at different points during the life cycle of a digital intervention to assess its efficacy and potential harm to users. It is crucial to recognize that unlike analog tools, digital interventions constantly evolve, posing challenges to inflexible evaluation methods such as RCTs. Potential risks include high dropout rates, decreased adherence, and nonsignificant results. However, existing regulations do not explicitly advocate for other evaluation methodologies. Our research highlighted the necessity of overcoming the gap between regulatory demands to demonstrate safety and efficacy of medical apps and evolving scientific practices, ensuring that digital health innovation is evaluated and regulated in a way that considers the unique characteristics of mobile medical devices.

Sections du résumé

BACKGROUND BACKGROUND
The rapid proliferation of medical apps has transformed the health care landscape by giving patients and health care providers unprecedented access to personalized health information and services. However, concerns regarding the effectiveness and safety of medical apps have raised questions regarding the efficacy of randomized controlled trials (RCTs) in the evaluation of such apps and as a requirement for their regulation as mobile medical devices.
OBJECTIVE OBJECTIVE
This study aims to address this issue by investigating alternative methods, apart from RCTs, for evaluating and regulating medical apps.
METHODS METHODS
Using a qualitative approach, a focus group study with 46 international and multidisciplinary public health experts was conducted at the 17th World Congress on Public Health in May 2023 in Rome, Italy. The group was split into 3 subgroups to gather in-depth insights into alternative approaches for evaluating and regulating medical apps. We conducted a policy analysis on the current regulation of medical apps as mobile medical devices for the 4 most represented countries in the workshop: Italy, Germany, Canada, and Australia. We developed a logic model that combines the evaluation and regulation domains on the basis of these findings.
RESULTS RESULTS
The focus group discussions explored the strengths and limitations of the current evaluation and regulation methods and identified potential alternatives that could enhance the quality and safety of medical apps. Although RCTs were only explicitly mentioned in the German regulatory system as one of many options, an analysis of chosen evaluation methods for German apps on prescription pointed toward a "scientific reflex" where RCTs are always the chosen evaluation method. However, this method has substantial limitations when used to evaluate digital interventions such as medical apps. Comparable results were observed during the focus group discussions, where participants expressed similar experiences with their own evaluation approaches. In addition, the participants highlighted numerous alternatives to RCTs. These alternatives can be used at different points during the life cycle of a digital intervention to assess its efficacy and potential harm to users.
CONCLUSIONS CONCLUSIONS
It is crucial to recognize that unlike analog tools, digital interventions constantly evolve, posing challenges to inflexible evaluation methods such as RCTs. Potential risks include high dropout rates, decreased adherence, and nonsignificant results. However, existing regulations do not explicitly advocate for other evaluation methodologies. Our research highlighted the necessity of overcoming the gap between regulatory demands to demonstrate safety and efficacy of medical apps and evolving scientific practices, ensuring that digital health innovation is evaluated and regulated in a way that considers the unique characteristics of mobile medical devices.

Identifiants

pubmed: 39348678
pii: v26i1e54814
doi: 10.2196/54814
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e54814

Informations de copyright

©Laura Maaß, Robert Hrynyschyn, Martin Lange, Alexandra Löwe, Kathrin Burdenski, Kaley Butten, Sebastian Vorberg, Mariam Hachem, Aldo Gorga, Vittorio Grieco, Vincenzo Restivo, Giuseppe Vella, Marlien Varnfield, Felix Holl. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 30.09.2024.

Auteurs

Laura Maaß (L)

University of Bremen, SOCIUM - Research Center on Inequality and Social Policy, Department of Health, Long Term Care and Pensions, Bremen, Germany.
Leibniz ScienceCampus Digital Public Health, Bremen, Germany.
Digital Health Section, European Public Health Association (EUPHA), Utrecht, Netherlands.

Robert Hrynyschyn (R)

Leibniz ScienceCampus Digital Public Health, Bremen, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Health and Nursing Science, Institute of Health and Nursing Science, Berlin, Germany.

Martin Lange (M)

Department of Fitness & Health, IST University of Applied Sciences, Düsseldorf, Germany.

Alexandra Löwe (A)

Department of Fitness & Health, IST University of Applied Sciences, Düsseldorf, Germany.

Kathrin Burdenski (K)

School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom.

Kaley Butten (K)

Australian eHealth Research Centre (CSIRO), Brisbane, Australia.

Sebastian Vorberg (S)

QuR.digital - Vorberg.law, Hamburg, Germany.
Bundesverband Internetmedizin eV, Hamburg, Germany.

Mariam Hachem (M)

Department of Medicine, Austin Health, Faculty of Dentistry, Medicine and Health Sciences, University of Melbourne, Melbourne, Australia.
Australian Centre for Accelerating Diabetes Innovations, Faculty of Dentistry, Medicine and Health Sciences, University of Melbourne, Melbourne, Australia.

Aldo Gorga (A)

Department of Sciences of Public Health and Pediatrics, University of Turin, Turin, Italy.

Vittorio Grieco (V)

Department of Medical, Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, Catania, Italy.

Vincenzo Restivo (V)

School of Medicine, University of Enna, Enna, Italy.

Giuseppe Vella (G)

Department of Health Promotion, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) "G. D'Alessandro", University of Palermo, Palermo, Italy.

Marlien Varnfield (M)

Australian eHealth Research Centre (CSIRO), Brisbane, Australia.

Felix Holl (F)

Leibniz ScienceCampus Digital Public Health, Bremen, Germany.
DigiHealth Institute, Neu-Ulm University of Applied Sciences, Neu-Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH